Litcius/Paper detail

TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer

Marc Pujalte‐Martin, Delphine Borchiellini, Brice Thamphya, Aline Guillot, Jean-Baptiste Paoli, Dominique Besson, Werner Hilgers, Frank Priou, Claude El Kouri, Benjamin Hoch, Jean‐Laurent Deville, Renaud Schiappa, Sandrine Pacquelet, G. Milano, Jean‐François Tanti, Frédéric Bost, Jean-Marc Ferrero

2021Clinical Genitourinary Cancer42 citationsDOI

Topics & Concepts

MedicineDocetaxelProstate cancerPlaceboOncologyMetforminInternal medicineRandomized controlled trialChemotherapyUrologyCancerPathologyAlternative medicineInsulinMetabolism, Diabetes, and CancerCancer, Lipids, and MetabolismProstate Cancer Treatment and Research
TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer | Litcius